The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | New combination therapies in HER2-expressing gastric cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the DESTINY-Gastric01 trial (NCT03329690) investigating IHC 1-positive (IHC1+) and IHC 2-positive (IHC2+)/ISH-negative (ISH-) patients with HER2-expressing gastric cancer. Antibody-drug conjugate (ADC) trastuzumab derutexcan (T-DXd) was administered in patients, however, to enhance activity, T-DXd will be investigated in combination with capecitabine, nivolumab and oxaliplatin, in an upcoming Phase Ib trial. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role – ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding – Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
